First-in-Human Single Ascending and Multiple Dose of GLPG0634

Double-blind Placebo-controlled Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG0634 in Healthy Subjects

The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) and multiple (MD) oral doses of GLPG0634 compared to placebo (with and without food).

Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0634 after single and multiple oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.

Inclusion Criteria:

• healthy male, age 40-60 years
• body mass index (BMI) between 18-30 kg/m², inclusive.

Exclusion Criteria:

• any condition that might interfere with the procedures or tests in the study
• smoking
• drug or alcohol abuse